This retrospective study found no benefit of a disease management program compared with usual care on utilization of secondary prevention pharmacotherapies in postmyocardial infarction patients.
Vicky Chan, PharmD
Advertisement
Articles by Vicky Chan, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
2
Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment
3
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
4
CKD Stage, Proteinuria Tied to Higher HCRU in IgAN
5